CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 16 enrolled
Drug / intervention
ARGOS-IO Sensor Pressure Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03651336
NCT03651336N/ACompleted

A Prospective, Open-label, Multicenter Clinical Follow-up Investigation of the ARGOS-01 and ARGOS-02 Patients to Assess the Long-term Safety and Performance of the ARGOS-IO Intraocular Pressure Sensor System in Subjects With Primary Open Angle Glaucoma (POAG)

Implandata Ophthalmic Products GmbH·interventional·Posted Aug 29, 2018·Updated May 9, 2025

In Brief

A clinical study evaluating ARGOS-IO Sensor Pressure System for Primary Open-angle Glaucoma. Completed, enrolled 16 participants across 4 sites.

Detailed Summary

The purpose of this study is to evaluate the long-term safety and performance of the ARGOS-IO system in patients with Primary Open Angle Glaucoma (POAG)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedAug 29, 2018
Enrollment StartAug 15, 2018
Primary CompletionApr 27, 2022
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 7.8 years ago

Interventions

ARGOS-IO Sensor Pressure Systemdevice

The ARGOS-IO Pressure sensor have been additionally implanted during local routine working procedures for cataract surgery in Patients with Primary Open Angle Glaucoma (POAG) and indicated cataract surgery in previous studies ARGOS-01 and ARGOS-02